Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

JAKing up hematopoietic proliferation.

Kevin Shannon1, Richard A Van Etten

  • 1Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA. kevins@itsa.ucsf.edu

Cancer Cell
|April 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma.

Journal of hepatology·2026
Same author

Reducing Emergency Diagnostic Uncertainty with TRACE: Triage and Risk Assessment via Cost Estimation.

The western journal of emergency medicine·2026
Same author

Quality and Usability Evaluation of U.S. Clinical Informatics Fellowship Websites.

Applied clinical informatics·2026
Same author

De novo design of Ras isoform selective binders.

Cell chemical biology·2026
Same author

Spatial transcriptomics reveals altered communities and drivers of aberrant epithelia and pro-fibrotic fibroblasts in interstitial lung diseases.

Cell genomics·2026
Same author

Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling.

bioRxiv : the preprint server for biology·2025
Same journal

Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis.

Cancer cell·2026
Same journal

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026
Same journal

Intratumoral B cells under stress.

Cancer cell·2026
Same journal

Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth.

Cancer cell·2026
Same journal

Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.

Cancer cell·2026
Same journal

OpenIO: An open framework for AI-native immunotherapy.

Cancer cell·2026
See all related articles

A JAK2 kinase mutation is found in most myeloproliferative disorders (MPDs). This discovery offers new diagnostic approaches and potential drug targets for MPDs.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Myeloproliferative disorders (MPDs) are characterized by deregulated proliferation and survival pathways.
  • A common molecular theme in MPDs involves mutations affecting key signaling pathways.

Purpose of the Study:

  • To investigate the role of specific mutations in the pathogenesis of MPDs.
  • To identify novel molecular targets for the diagnosis and treatment of MPDs.

Main Methods:

  • Analysis of patient cohorts with polycythemia vera, essential thrombocythemia, and chronic idiopathic myelofibrosis.
  • Functional studies of identified mutations in the JAK2 kinase.
  • In vitro assays assessing cell growth and signaling pathways.
  • In vivo studies using mouse models to evaluate disease development.

Related Experiment Videos

Main Results:

  • An amino acid substitution in the JAK2 kinase was identified in most patients with polycythemia vera and some with essential thrombocythemia and chronic idiopathic myelofibrosis.
  • The JAK2 mutation resulted in erythropoietin-independent cell growth in vitro.
  • The mutation led to deregulation of signaling pathways downstream of JAK2.
  • The JAK2 mutation induced polycythemia in a mouse model.

Conclusions:

  • The JAK2 kinase mutation is a significant factor in the pathogenesis of MPDs.
  • This finding provides new avenues for the diagnosis and classification of MPDs.
  • The JAK2 mutation represents a potential molecular target for novel therapeutic strategies in MPDs.